Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Butylphthalide in Multiple System Atrophy
NCT07518810Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple system atrophy (MSA) comparing NBP treatment group with Placebo control group (2 arms). Primary endpoint: Main symptom control of MSA at 12 months. Started Aug 2026; status: recruiting.
02
Drugs
butylphthalide
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT07518810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518810.